leadf
logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy - Result of AGM and Directorate Changes

RNS Number : 5135U
Advanced Oncotherapy PLC
29 July 2020
 

29 July 2020

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Result of AGM and Directorate Changes

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed on a poll. The results of the proxy voting for the AGM are set out below:

 

Resolution

Total votes For1

% of votes cast2

Total Votes Against

% of votes cast2

Votes Withheld3

1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31st December 2019.

172,734,768

99.95

90,000

0.05

3,013

2. To re-appoint Michael Bradfield as a Director of the Company.

172,734,286

99.95

93,330

0.05

165

3. To re-appoint Hans von Celsing as a Director of the Company.

172,734,286

99.95

93,330

0.05

165

4. To re-appoint Prof. Steve Myers as a Director of the Company.

172,824,286

99.99

830

0.01

2,665

5. To re-appoint Dr Nick Plowman as a Director of the Company.

172,824,286

99.99

830

0.01

2,665

6. To re-appoint Nicolas Serandour as a Director of the Company.

172,824,286

99.99

830

0.01

2,665

7. To re-appoint Dr Michael Sinclair as a Director of the Company.

172,826,786

99.99

995

0.01

0

8. To re-appoint Dr Enrico Vanni as a Director of the Company.

172,736,786

99.95

90,830

0.05

165

9. To re-appoint Renhua Zhang as a Director of the Company.

172,823,286

99.99

1,830

0.01

2,665

10. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company to hold office until the conclusion of the next AGM at which accounts are laid before the Company

172,826,951

100.00

0

0.00

830

11. To authorise the Directors to determine the remuneration of the

Auditors.

172,823,451

99.90

3,500

0.01

830

12. Authority to allot shares

172,822,517

99.99

5,264

0.01

0

13. Authority to disapply pre-emption rights

172,703,050

99.93

124,566

0.07

165

 

Notes

 

1.   Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.   Percentage of votes cast excludes Votes Withheld

3.   Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

 

Directorate Changes 

 

As announced on 8 June 2020, Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin "Allen" Han and Dr Yuelong Huang (all Non-Executive Directors of the Company) did not seek re-election at the Company's AGM. Accordingly, these directors have now stepped down from the Board with immediate effect and consequently the size of the Board has decreased from 12 to 8 people.

 

- ENDS -

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Broking)

Tel: +44 (0) 20 3328 5656



FTI Consulting (Financial PR & IR)

[email protected]

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGKZGZNFLGGGZM

Quick facts: Advanced Oncotherapy PLC

Price: 30.5

Market: LSE
Market Cap: £93.44 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: Lloyds ends PPI headache; Sirius Minerals 'is quality' says...

Headlines from the Proactive UK newsroom. Anglo American (LON:AAL) has repeated that Sirius Minerals (LON:SXX) is a “quality” investment which is expected to “fit well” with the FTSE 100 group’s strategy. Anglo, which has made a bid for the firm, says the project in North Yorkshire is...

on 20/2/20